Ex Vivo Treatment with a Novel Synthetic Aminoglycoside NB54 in Primary Fibroblasts from Rett Syndrome Patients Suppresses MECP2 Nonsense Mutations

Similar Items

• Readthrough of nonsense mutations in Rett syndrome: evaluation of novel aminoglycosides and generation of a new mouse model
  od: Brendel, Cornelia, i dr.
  Izdano: (2010)
• Erratum to: Readthrough of nonsense mutations in Rett syndrome: evaluation of novel aminoglycosides and generation of a new mouse model
  od: Brendel, Cornelia, i dr.
  Izdano: (2013)
• Development of novel aminoglycoside (NB54) with reduced toxicity and enhanced suppression of disease-causing premature stop mutations
  od: Nudelman, Igor, i dr.
  Izdano: (2009)
• Suppression of CFTR premature termination codons and rescue of CFTR protein and function by the synthetic aminoglycoside NB54
  od: Rowe, Steven M., i dr.
  Izdano: (2011)
• A comparative evaluation of NB30, NB54 and PTC124 in translational read-through efficacy for treatment of an USH1C nonsense mutation
  od: Goldmann, Tobias, i dr.
  Izdano: (2012)